Investing in Homebuilder Stocks 2019

It takes an unusual combination of fundamentals and attitudes to create a stock opportunity appropriate for multiple investor types. Such is the case for homebuilders. Housing indicators are positive, results are good, growth is happening. At the same time, general views are negative, resulting from last year’s underperformance and this year’s misinterpretation of housing indicators (particularly existing and new home sales). Hence, growth, value and contrarian investors as well as speculators can find things to like about homebuilder stocks. (Income investors, not so much, unless you are willing to give weight to 10% earnings yields.)

During the fourth quarter 2018 bear market and, again, in this month's weak stock market, homebuilder stocks outperformed. However, the bear market outperformance was hidden because the stocks were basically flat, so investors maintained their negative view of the group.

Read the full article at Forbes.

Don’t Stop Here

More To Explore

Market Brief: AI Risks and Fed Minutes Incoming

Market Snapshot Market Pulse: U.S. stocks edged sideways, buoyed by fresh AI chatter that kept tech afloat while industrial sectors shrugged off supply-chain jitters. Bond

AARD: 56% Drop Sparks Urgent Investor Scrutiny!

Overview: Aardvark Therapeutics, Inc. (Nasdaq: AARD) is a clinical-stage biotech focused on therapies for metabolic diseases and Prader-Willi Syndrome (PWS) – a rare genetic disorder

Gene-Editing Goldrush Meets AI and ETF Plays

Opening Recap Market Pulse: Gene-editing fervor rippled through biotech circles after a Mordor Intelligence report flagged double-digit growth in cell line development through 2031. Down